# A Trial of Injectable SHR-A1811 in Combination With Pyrotinib or SHR-1316 in Subjects With Advanced Non-small Cell Lung Cancer

Source: https://onco.cc/trials/nct05482568/  
OnCo record `nct05482568` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Adebrelimab, Pyrotinib and Trastuzumab rezetecan in non-small-cell lung cancer, run by Jiangsu HengRui Medicine Co., Ltd., now recruiting.

## Summary

A Trial of Injectable SHR-A1811 in Combination With Pyrotinib or SHR-1316 in Subjects With Advanced Non-small Cell Lung Cancer is a phase 1/2 interventional study registered as NCT05482568 by Jiangsu HengRui Medicine Co., Ltd., with 324 participants planned, started 2022-09-15 and due to reach its primary completion in 2026-12. Interventions recorded: SHR-A1811 & Pyrotinib/SHR-A1811 & SHR-1316.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05482568
- Phase: 1/2
- Setting: Phase IB/II Clinical Study of the Safety, Tolerability, Pharmacokinetics, and Efficacy of Injectable SHR-A1811 in Combination With Pyrotinib or SHR-1316 in Subjects With Advanced Non-small Cell Lung Cancer With HER2
- Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- Enrolled: 324

## Sources

- ClinicalTrials.gov NCT05482568: https://clinicaltrials.gov/study/NCT05482568

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- drugs: [Adebrelimab](https://onco.cc/drugs/adebrelimab/), [Pyrotinib](https://onco.cc/drugs/pyrotinib/), [Trastuzumab rezetecan](https://onco.cc/drugs/trastuzumab-rezetecan/)
- companies: [Jiangsu Hengrui Pharmaceuticals](https://onco.cc/companies/hengrui/)

---
JSON: https://onco.cc/api/v1/entities/nct05482568.json